The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Claire Lin, Matthew J. Hadfield, Ariana Santopietro, Galina Lagos, Liang Cheng, Wafik S. El‐Deiry, Rahul Aggarwal, Anthony Mega, Elias S. Hyams, Benedito A. Carneiro
Abstract
Advances in antibody-drug conjugate (ADC) technology and identification of new antigen targets are repositioning ADCs as a promising therapeutic platform for metastatic castration-resistant prostate cancer (mCRPC). This review summarizes recent progress in ADC payload and linker chemistry, highlights membrane antigens in prostate cancer that have demonstrated encouraging antitumor activity in clinical trials, and addresses strategies to mitigate off-target toxicity. These advances position ADCs to transform the therapeutic landscape of mCRPC.
Topics & Concepts
Prostate cancerMedicineConjugateGlutamate carboxypeptidase IICancerCancer researchIdentification (biology)LinkerAntigenOncologyPayload (computing)Prostate-specific antigenClinical PracticeMonoclonal antibodyImmunotherapyTherapeutic approachInternal medicineProstateCancer immunotherapyCancer treatmentMetastasisCancer therapyProstate Cancer Treatment and ResearchHER2/EGFR in Cancer ResearchRadiopharmaceutical Chemistry and Applications